Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Commercial biotech firm Millenia Hope has initiated a second company-sponsored WHO-monitored trial in the Republic of Central Africa to test its anti-malaria treatment, MMH8 Malarex.
Subscribe to our email newsletter
The 360-patient trial will be monitored by the World Health Organization (WHO), UNICEF and the Pasteur Institute, and follows Millenia Hope’s recent success with three efficacy trials.
The new Millenia Hope trial is an extended study in a pediatric patient group with non-complicated malaria and will be carried out in three major cities in the Republic of Central Africa (RCA).
A five-day treatment of MMH reduces the fever in the majority of patients within three to four days and significantly decreases parasite density in five days. In all patients the parasite density was decreased to zero within seven days, and the disease-associated anemia improved significantly during the 14-day follow-up period.
“MMH Malarex has a major impact on drug-resistant strains of malaria when administered to patients in areas where these are the prevalent strains,” said Leonard Stella, CEO of Millenia Hope. “We are ecstatic that the WHO, UNICEF and the Pasteur Institute are monitoring this study and have approved the protocol. This is a major step forward for the company to interest these organizations in our products.”
Malaria claims nearly three million lives annually and its global market is estimated at $10 billion.